Oxidative Status in Children With Autoimmune Thyroiditis

Status Completed

Clinical Trial Summary

Oxidative status in autoimmune thyroiditis was not investigated previously in children and adolescents. We investigated oxidant and antioxidant systems in a cohort of Egyptian children and adolescents with AIT to explore their relation with biomarkers of autoimmunity and thyroid function.

Clinical Trial Description

Methods: A case control study included 32 children with autoimmune thyroiditis and 32 healthy subjects with matching age and sex were included as a control group. Thorough history, examination, thyroid ultrasound, measurement of thyroid-stimulating hormone (TSH) and free thyroxine (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers. Results: Overt hypothyroidism was detected in 23/32 while subclinical hypothyroidism was detected in 9/32 of the studied patients. Malondialdehyde levels were significantly elevated while total antioxidant capacity levels were significantly decreased in autoimmune thyroiditis patients compared with healthy controls. The difference was more evident in patients with overt hypothyroidism than those with subclinical hypothyroidism. We also observed a significant positive correlation between anti-thyroid peroxidase antibodies levels and age, TSH, malondialdehyde, thyroid volume and a negative correlation with total antioxidant capacity and thyroxine .

Conclusions: The high serum malondialdehyde and lower total antioxidant capacity levels in patients with autoimmune thyroiditis and the correlation of thyroid antibodies with biomarkers of oxidative stress may reflect the role of autoimmunity in the development of oxidative stress. Future studies are needed for evaluation of the antioxidant therapy for autoimmune thyroiditis patients. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02318160
Study type	Observational [Patient Registry]
Source	Assiut University
Contact
Status	Completed
Phase	N/A
Start date	January 2014
Completion date	March 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06249074` - Gluten-free Diet in Women With Autoimmune Thyroiditis	N/A
Completed	`NCT02240563` - Low Level Laser Therapy for Autoimmune Thyroiditis	N/A
Not yet recruiting	`NCT05544448` - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases	N/A
Completed	`NCT03289403` - The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis	Phase 2
Completed	`NCT01129492` - Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis	Phase 2
Completed	`NCT02013479` - Selenium Supplementation in Autoimmune Thyroiditis	N/A
Completed	`NCT03048708` - Thyroid in Bariatric Surgery	N/A
Completed	`NCT03498417` - Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
Completed	`NCT05680376` - Thyroid Hormone Values and Anti-thyroid Peroxidase Antibody Positivity in Recurrent Pregnancy Loss
Completed	`NCT04754607` - Effects of Low-Level Laser Therapy on Oxidative Stress Levels...	N/A
Completed	`NCT04600349` - Identity Oriented Psychotrauma Therapy on Hashimoto in Adults	N/A
Completed	`NCT00271427` - Selenium Treatment in Autoimmune Thyroiditis (AIT)	N/A
Completed	`NCT02644707` - Selenium Supplementation in Youths With Autoimmune Thyroiditis	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.